⌘K
Loading ticker…
As of 2026-08-24, Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) has a 3-month relative strength percentile of 99 and a leadership percentile of 99 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 95. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.0%, relative volume 0.94×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AMLX is in a stage 2 uptrend, week 10. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 83.8% / 140.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
AMLX is held by 23 ETFs as of May 2026. Top owner: VTWO at 0.04% weight, $7M notional. Top 3 carry $15M.
Held by 56 ETFs · $160M across latest filings · largest weight 1.79% (XPH).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.04% | $7M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.03% | $6M | — |
| VHTVanguard Health Care ETF | 0.01% | $3M | — |
| VFMO | 0.11% | $2M | −0.08 pp |
| SBIO | 1.01% | $2M | −0.07 pp |
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.05% |
| $1M |
| — |
| VTWG | 0.06% | $948K | −0.01 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $844K | — |
| FSCC | 0.25% | $679K | −0.05 pp |
| GSSC | 0.06% | $626K | −0.02 pp |
Showing 10 of 23 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AMLX Jan avg: 7.40% median: 7.38% win: 75% σ: 8.94% n: 4 2022-04-12 → 2026-07-31 | AMLX Feb avg: 0.67% median: -1.99% win: 50% σ: 13.91% n: 4 2022-04-12 → 2026-07-31 | AMLX Mar avg: -25.28% median: -12.05% win: 25% σ: 40.98% n: 4 2022-04-12 → 2026-07-31 | AMLX Apr avg: -1.69% median: -3.20% win: 40% σ: 32.85% n: 5 2022-04-12 → 2026-07-31 | AMLX May avg: -5.76% median: -4.97% win: 20% σ: 5.88% n: 5 2022-04-12 → 2026-07-31 | AMLX Jun avg: 32.82% median: 24.47% win: 80% σ: 49.30% n: 5 2022-04-12 → 2026-07-31 | AMLX Jul avg: 19.13% median: 13.08% win: 100% σ: 13.59% n: 5 2022-04-12 → 2026-07-31 | AMLX Aug avg: 2.51% median: 0.64% win: 50% σ: 11.90% n: 4 2022-04-12 → 2026-07-31 (current) | AMLX Sep avg: 21.82% median: 28.21% win: 75% σ: 29.33% n: 4 2022-04-12 → 2026-07-31 | AMLX Oct avg: 21.24% median: 14.61% win: 75% σ: 34.05% n: 4 2022-04-12 → 2026-07-31 | AMLX Nov avg: 1.13% median: 5.07% win: 75% σ: 9.82% n: 4 2022-04-12 → 2026-07-31 | AMLX Dec avg: -12.72% median: -11.53% win: 25% σ: 15.98% n: 4 2022-04-12 → 2026-07-31 |